Twist Bioscience Corporation (TWST)

NASDAQ: TWST · Real-Time Price · USD
47.94
+4.32 (9.90%)
At close: Dec 20, 2024, 4:00 PM
49.00
+1.06 (2.21%)
After-hours: Dec 20, 2024, 5:38 PM EST
9.90%
Market Cap 2.85B
Revenue (ttm) 312.97M
Net Income (ttm) -208.73M
Shares Out 59.36M
EPS (ttm) -3.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,918,845
Open 43.29
Previous Close 43.62
Day's Range 42.89 - 48.00
52-Week Range 27.41 - 60.90
Beta 1.84
Analysts Buy
Price Target 52.33 (+9.16%)
Earnings Date Jan 31, 2025

About TWST

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and ... [Read more]

Sector Healthcare
IPO Date Oct 31, 2018
Employees 923
Stock Exchange NASDAQ
Ticker Symbol TWST
Full Company Profile

Financial Performance

In 2024, Twist Bioscience's revenue was $312.97 million, an increase of 27.69% compared to the previous year's $245.11 million. Losses were -$208.73 million, 2.01% more than in 2023.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for TWST stock is "Buy." The 12-month stock price forecast is $52.33, which is an increase of 9.16% from the latest price.

Price Target
$52.33
(9.16% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Twist Bioscience to Present at 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announce...

2 days ago - Business Wire

Twist Bioscience: Path To Profitability Beginning To Take Shape

Twist Bioscience's SynBio and NGS segments continue to generate strong growth, despite macro challenges. The prospects of the biopharma segment are uncertain, highlighted by the sale of milestones and...

22 days ago - Seeking Alpha

Twist Bioscience: A Post-Earnings Assessment

Twist Biosciences just posted a solid Q4, which had the stock rising in trading Monday. However, despite impressive sales growth, Twist Biosciences remains unprofitable, with projected losses for seve...

4 weeks ago - Seeking Alpha

Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps

On Monday, Twist Bioscience Corporation TWST reported a fourth-quarter loss per share of 59 cents, beating the consensus loss of 70 cents.

4 weeks ago - Benzinga

Twist Bioscience Corporation (TWST) Q4 2024 Earnings Call Transcript

Twist Bioscience Corporation (NASDAQ:TWST) Q4 2024 Earnings Conference Call November 18, 2024 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs Emily Leproust - CEO and Co-Found...

4 weeks ago - Seeking Alpha

Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

4 weeks ago - Business Wire

Twist Bioscience to Present at 7th Annual Evercore HealthCONx Conference

SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform...

5 weeks ago - Business Wire

Twist Bioscience's Earnings Preview: Partnerships And Valuation Make It A 'Buy'

Since I last covered it, Twist Bioscience has made significant strides. They have secured new partnerships, launched innovative products, and secured strategic financial agreements. TWST's valuation m...

6 weeks ago - Seeking Alpha

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers ...

6 weeks ago - Business Wire

Twist Bioscience Launches FlexPrep™ Ultra-High Throughput Library Preparation Kit for Applications in Agrigenomics and Population Genomics

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

7 weeks ago - Business Wire

Twist Bioscience to Report Fiscal 2024 Fourth Quarter and Full Year Financial Results on Monday, November 18, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

2 months ago - Business Wire

Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

Other symbols: XOMA
2 months ago - Business Wire

Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

2 months ago - Business Wire

Twist Bioscience Achieves LEED Certification for Sustainable Operations and Maintenance

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

3 months ago - Business Wire

Twist Bioscience Releases 2024 Corporate Responsibility Report and Quantifies Carbon Footprint of Oligo Manufacturing Process for NGS Target Enrichment Panels

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

3 months ago - Business Wire

Twist Bioscience to Present at Baird Global Healthcare Conference 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

4 months ago - Business Wire

Twist Bioscience Expands Gene Offering With Long Gene Fragments up to 5.0kb

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

4 months ago - Business Wire

Twist Bioscience and bitBiome Announce Strategic Collaboration and First Offering to Deliver One-of-a-Kind Enzymes for Biocatalysis

SOUTH SAN FRANCISCO, Calif. & TOKYO--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its ...

4 months ago - Business Wire

Twist Bioscience: Lowered Biopharma Expectations Amid Financial Strain (Rating Downgrade)

Twist Bioscience reported revenue of $81.5 million in Q2 (fiscal Q3), marking a 28% increase from Q2, 2023. Twist's biopharma segment underperformed, contributing to a significant impairment charge. T...

4 months ago - Seeking Alpha

Twist Bioscience Corporation (TWST) Q3 2024 Earnings Call Transcript

Twist Bioscience Corporation (NASDAQ:TWST) Q3 2024 Earnings Conference Call August 2, 2024 8:00 AM ET Company Participants Angela Bitting - Senior Vice President, Corporate Affairs Emily Leproust - C...

5 months ago - Seeking Alpha

Twist Bioscience Beats Q3 Earnings Forecast, Plans To Achieve 50% Gross Margin By Fiscal Year 2025

Friday, Twist Bioscience Corporation TWST reported a third-quarter adjusted EPS loss of $(0.70), beating the consensus of $(0.77).

5 months ago - Benzinga

Twist Bioscience Reports Fiscal Third Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

5 months ago - Business Wire

Twist Bioscience: Growing Customer Base And Technology Platform Make Me Like This Stock

Twist Bioscience has seen significant share price growth in the past year, driven by innovative DNA synthesis technology and strong revenue growth. Despite challenges in the life sciences industry, th...

5 months ago - Seeking Alpha

Twist Bioscience Announces Clinical Progression of Pure Biologics' Antibody Candidate Discovered Using Twist's Antibody Libraries

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

5 months ago - Business Wire

Twist Bioscience to Report Fiscal 2024 Third Quarter Financial Results on Friday, August 2, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

5 months ago - Business Wire